Bellicum announces first reported use of caspacide® safety switch to mitigate car-t cell toxicity

Houston, march 04, 2021 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of a case report using the company's caspacide (inducible caspase-9, or ic9) safety switch. the letter to the editor titled “utility of safety switch to abrogate cd 19 car t cell-associated neurotoxicity” appeared as an ahead-of-print publication in the digital edition of blood, a journal published by the american society of hematology. link to article.
BLCM Ratings Summary
BLCM Quant Ranking